SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its earnings update, which signaled near-term caution due to anticipated supply constraints despite a strong prior quarter. This has sparked a polarized debate, with many community members labeling the sharp price movement as an expected correction for an overvalued asset, while bullish investors emphasize the company's long-term strategic importance in US chip manufacturing and potential future foundry partnerships.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending following the appointment of OpenAI's Chelsea Voss to its Board of Directors, signaling a strong focus on advanced AI and quantum-class computing. This strategic move, coupled with an effective reverse stock split and a notably low public float, is driving intense community discussions around potential undervaluation and the possibility of a short squeeze.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following promising Phase 2 data for its glioblastoma treatment, with conversations highlighting that median overall survival has not yet been reached, signaling exceptional patient outcomes for this challenging cancer. The community is widely discussing the positive implications of this data, along with high short interest, as potential drivers for significant upward momentum. Many express strong conviction in the company's innovative immunotherapy platform and future catalysts.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is seeing intense community discussion and significant price action, with many highlighting its Breakthrough Therapy Designation for Pemvidutide as a 'best in class' MASH and obesity drug with strong buyout potential. This surge is further fueled by discussions around the stock's undervaluation compared to peers and potential for a short squeeze, even as some skeptics label the rally a 'pump and dump' lacking new fundamental catalysts.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is generating significant conversation, with investors eagerly awaiting clarity on promised new hyperscaler deals and upcoming earnings amidst frustration over its lagging performance compared to AI/HPC data center peers. Despite a recent positive zoning approval for its Cayuga site and its Google-backed Fluidstack partnership, the community is actively debating perceived management silence and persistent short seller influence, seeking a catalyst to drive momentum and decouple it from Bitcoin's price movements.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is experiencing significant trading volume following news that its merger partner, Corvex, has secured a long-term NVIDIA H200 GPU deployment, aligning the company with the robust AI infrastructure sector. This catalyst, combined with an extremely low share float, has created highly polarized sentiment: many traders anticipate a massive short squeeze, while others caution that the move is unsustainable and risks further dilution.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares are experiencing significant upward momentum, nearing key psychological resistance levels, as mounting geopolitical tensions related to a potential Iran conflict fuel strong safe-haven demand. The community is hotly debating whether this parabolic rally is a genuine reflection of de-dollarization and anticipated rate cuts or an overextended bubble manipulated by large institutions, with many anticipating a sharp correction.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corporation is trending due to upcoming regulatory catalysts, particularly an anticipated FDA decision on an Afrezza label update for dose conversion, scheduled for January 23, 2026. The community is sharply divided, with bulls highlighting this and other 2026 milestones, including pediatric approval and strong Q4 revenue, as drivers for significant stock appreciation and potential M&A. Conversely, skeptics express frustration over perceived management inefficiencies, past performance of Afrezza, and potential stock dilution, leading to skepticism about sustained gains despite these anticipated developments.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is experiencing a significant upward trend, fueled by recent analyst upgrades and strong price action, which has ignited intense debate among investors. The community is sharply divided, with bulls highlighting market resilience and squeeze potential, while bears frequently label the stock as a "scam" or "manipulated" due to its perceived disconnect from fundamentals and low trading volume. This contentious trend continues ahead of an impending judicial deadline concerning alleged stock manipulation and an anticipated earnings report.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is experiencing high volatility, driven by recent positive clinical data and analyst upgrades, but also by mixed community reactions to planned CEO stock sales. Investor discussions are heavily influenced by ongoing buyout rumors and the company's place within a rapidly evolving gene-editing sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$JEM FULLPORTING BOTTOM $.23 
 
@Paraboljoker ON IT FOR A 500-100% MOVE!! 
 
$XTKG $BNAI $WORX $SPHL lfg !

$JEM $XTKG $BNAI $WORX $SPHL 

Jem has the looks